ethyl 3-(4-fluorophenyl)-1-methyl-1H-indole-2-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 3-(4-fluorophenyl)-1-methyl-1H-indole-2-carboxylate
• 英文别名: ethyl 3-(4'-fluorophenyl)-1-methylindole-2-carboxylate；ethyl 3-(4-fluorophenyl)-1-methylindole-2-carboxylate
• 化学式: C₁₈H₁₆FNO₂
• 分子量: 297.329
• InChiKey: QCGLHUHRKFCHJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  31.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3-(4-fluorophenyl)-1-methyl-1H-indole-2-carboxylate 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 N-(3,4-dichlorobenzyl)-N-(2-(dimethylamino)ethyl)-3-(4-fluorophenyl)-1-methyl-1H-indole-2-carboxamide
  参考文献：
  名称：

  Synthetic studies of centromere-associated protein-E (CENP-E) inhibitors: 1.Exploration of fused bicyclic core scaffolds using electrostatic potential map

  摘要：

  Centromere-associated protein-E (CENP-E), a mitotic kinesin that plays an important role in mitotic progression, is an attractive target for cancer therapeutic drugs. For the purpose of developing novel CENP-E inhibitors as cancer therapeutics, we investigated a fused bicyclic compound identified by high throughput screening, 4-oxo-4,5-dihydrothieno[3,4-clpyridine-6-carboxamide la. Based on this scaffold, we designed inhibitors for efficient binding at the L5 site in CENP-E utilizing homology modeling as well as electrostatic potential map (EPM) analysis to enhance CENP-E inhibitory activity. This resulted in a new lead, 5-bromoimidazo[l,2-a]pyridine 7, which showed potent CENP-E enzyme inhibition (IC50: 50 nM) and cellular activity with accumulation of phosphorylated histone H3 in HeLa cells. Our homology model and EPM analysis proved to be useful tools for the rational design of CENP-E inhibitors. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.067
• 作为产物：
  描述：

  ethyl 3-bromo-1-methyl-1H-indole-2-carboxylate 、 4-氟苯硼酸 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 caesium carbonate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 2.0h， 以80%的产率得到ethyl 3-(4-fluorophenyl)-1-methyl-1H-indole-2-carboxylate
  参考文献：
  名称：

  Synthetic studies of centromere-associated protein-E (CENP-E) inhibitors: 1.Exploration of fused bicyclic core scaffolds using electrostatic potential map

  摘要：

  Centromere-associated protein-E (CENP-E), a mitotic kinesin that plays an important role in mitotic progression, is an attractive target for cancer therapeutic drugs. For the purpose of developing novel CENP-E inhibitors as cancer therapeutics, we investigated a fused bicyclic compound identified by high throughput screening, 4-oxo-4,5-dihydrothieno[3,4-clpyridine-6-carboxamide la. Based on this scaffold, we designed inhibitors for efficient binding at the L5 site in CENP-E utilizing homology modeling as well as electrostatic potential map (EPM) analysis to enhance CENP-E inhibitory activity. This resulted in a new lead, 5-bromoimidazo[l,2-a]pyridine 7, which showed potent CENP-E enzyme inhibition (IC50: 50 nM) and cellular activity with accumulation of phosphorylated histone H3 in HeLa cells. Our homology model and EPM analysis proved to be useful tools for the rational design of CENP-E inhibitors. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.067

文献信息

• Intermediates in the synthesis of indole analogs of mevalonolactone and
  申请人：Sandoz Pharmaceuticals Corp.

  公开号：US04739073A1

  公开（公告）日：1988-04-19

  Compounds of the formula ##STR1## wherein one of R and R.sub.o is ##STR2## and the other is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom, C.sub.3-6 cycloalkyl or phenyl(CH.sub.2).sub.m --, wherein R.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R.sub.5 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R.sub.5a is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen, R.sub.5a must be hydrogen when R.sub.5 is hydrogen, not more than one of R.sub.4 and R.sub.5 is trifluoromethyl, not more than one of R.sub.4 and R.sub.5 is phenoxy, and not more than one of R.sub.4 and R.sub.5 is benzyloxy, R.sub.2 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.3-6 cycloalkyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R.sub.3 must be hydrogen when R.sub.2 is hydrogen, not more than one of R.sub.2 and R.sub.3 is trifluoromethyl, not more than one of R.sub.2 and R.sub.3 is phenoxy, and not more than one of R.sub.2 and R.sub.3 is benzyloxy, X is --(CH.sub.2).sub.n -- or --CH.dbd.CH--, wherein n is 0, 1, 2 or 3, and Z is ##STR3## wherein R.sub.6 is hydrogen or C.sub.1-3 alkyl, and R.sub.7 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, benzyl or M, wherein M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level, and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

  化合物的公式为##STR1##其中R和R.sub.o中的一个是##STR2##另一个是一级或二级C.sub.1-6烷基，不含不对称碳原子，C.sub.3-6环烷基或苯基(CH.sub.2).sub.m --，其中R.sub.4是氢，C.sub.1-3烷基，正丁基，异丁基，叔丁基，C.sub.1-3烷氧基，正丁氧基，异丁氧基，三氟甲基，氟，氯，苯氧基或苄氧基，R.sub.5是氢，C.sub.1-3烷基，C.sub.1-3烷氧基，三氟甲基，氟，氯，苯氧基或苄氧基，R.sub.5a是氢，C.sub.1-2烷基，C.sub.1-2烷氧基，氟或氯，m为1、2或3，条件是当R.sub.4为氢时，R.sub.5和R.sub.5a必须都是氢，当R.sub.5为氢时，R.sub.5a必须是氢，R.sub.4和R.sub.5中不超过一个是三氟甲基，不超过一个是苯氧基，不超过一个是苄氧基，R.sub.2是氢，C.sub.1-3烷基，正丁基，异丁基，叔丁基，C.sub.3-6环烷基，C.sub.1-3烷氧基，正丁氧基，异丁氧基，三氟甲基，氟，氯，苯氧基或苄氧基，R.sub.3是氢，C.sub.1-3烷基，C.sub.1-3烷氧基，三氟甲基，氟，氯，苯氧基或苄氧基，条件是当R.sub.2为氢时，R.sub.3必须是氢，R.sub.2和R.sub.3中不超过一个是三氟甲基，不超过一个是苯氧基，不超过一个是苄氧基，X是--(CH.sub.2).sub.n --或--CH.dbd.CH--，其中n为0、1、2或3，Z是##STR3##其中R.sub.6是氢或C.sub.1-3烷基，R.sub.7是氢，C.sub.1-3烷基，正丁基，异丁基，叔丁基，苯甲基或M，其中M是药学上可接受的阳离子，其用于抑制胆固醇生物合成和降低血液胆固醇水平，因此用于治疗高脂蛋白血症和动脉硬化，包括这种化合物的制药组合物和制造这种化合物的中间体和过程。
• [EN] ANALOGS OF MEVALOLACTONE AND DERIVATIVES THEREOF, PROCESSES FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS PHARMACEUTICALS
  申请人：——

  公开号：WO1984002131A1

  公开（公告）日：1984-06-07

  (EN) Compounds of formula I wherein one of R and Ro is II and the other is primary or secondary C1-6alkyl, C3-6cycloalkyl or phenyl-(CH2)m-, wherein R4 is hydrogen, C1-4alkyl, C1-4alkoxy, (except t-butoxy), trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5a is hydrogen, C1-2alkyl, C1-2alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R5 and R5a must be hydrogen when R4 is hydrogen, R5a must be hydrogen when R5 is hydrogen, not more than one of R4 and R5 is trifluoromethyl, not more than one of R4 and R5 is phenoxy and not more than one of R4 and R5 is benzyloxy, R2 is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-4alkoxy, (except t-butoxy), trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R3 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R3 must be hydrogen when R2 is hydrogen, not more than one of R2 and R3 is trifluoromethyl, not more than one of R2 and R3 is phenoxy, and not more than one of R2 and R3 is benzyloxy, X is -(CH2)n- or -CH=CH- (n=0, 1, 2 or 3), Z is III wherein R6 is hydrogen or C1-3alkyl in free acid form or in the form of a physiologically-hydrolysable and -acceptable ester or a lactone thereof or in salt form. These compounds are indicated for use as pharmaceuticals particularly for inhibiting cholesterol biosynthesis and treating atherosclerosis. (FR) Composés (I) où R ou Ro est (II) et l"autre est un phényl-(CH2)m-, un cycloalcoyl comportant entre 3 et 6 atomes de carbone ou un alcoyle primaire ou secondaire comportant entre 1 et 6 atomes de carbone, où R4 est un hydrogène, un alcoyle comportant entre 1 et 4 atomes de carbone, un alcoxy comportant entre 1 et 4 atomes de carbone, (à l"exception d"un t-butoxy), un trifluorométhyl, un fluoro, un chloro, un phénoxy ou un benzyloxy, R5 est un hydrogène, un alcoyle comportant entre 1 et 3 atomes de carbone, un alcoxy comportant entre 1 et 3 atomes de carbone, un trifluorométhyl, un fluoro, un chloro, un phénoxy ou un benzyloxy, R5a est un hydrogène, un alcoyle comportant 1 ou 2 atomes de carbone, un alcoxy comportant un ou deux atomes de carbone, un fluoro ou un chloro, et m est égal à 1, 2 ou 3, à condition que R5 et R5a représentent un hydrogène lorsque R4 est un hydrogène, que R5a soit un hydrogène lorsque R5 est un hydrogène, que pas plus d"un des groupes R4 et R5 soit un trifluorométhyl, que pas plus d"un des groupes R4 et R5 soit un phénoxy et que pas plus d"un des groupes R4 et R5 soit un benzyloxy, R2 est un hydrogène, un alcoyle comportant entre 1 et 4 atomes de carbone, un cycloalcoyl comportant entre 3 et 6 atomes de carbone, un alcoxy comportant entre 1 et 4 atomes de carbone, (à l"exception d"un t-butoxy), un trifluorométhyl, un fluoro, un chloro, un phénoxy ou un benzyloxy, R3 est un hydrogène, un alcoyle comportant entre 1 et 3 atomes de carbone, un alcoxy comportant entre 1 et 3 atomes de carbone, un trifluorométhyl, un fluoro, un chloro, un phénoxy ou un benzyloxy, à condition que R3 soit un hydrogène lorsque R2 est un hydrogène, que pas plus d"un des groupes R2 et R3 soit un trifluorométhyl, que pas plus d"un des groupes R2 et R3 soit un phénoxy et que pas plus d"un des groupes R2 et R3 soit un benzyloxy, X est -(CH2)n- ou -CH égal CH- (n égal 0, 1, 2 ou 3), Z est (III), où R6 est un hydrogène ou un alcoyle comportant entre 1 et 3 atomes de carbone sous forme d"acide libre, sous la forme d"un ester physiologiquement hydrolisable et physiologiquement acceptable ou d"un lactone de celui-ci, o u sous forme de sel. Ces composés sont indiqués pour une utilisation en tant que produits pharmaceutiques en particulier pour l"inhibition de la biosynthèse du cholestérol et le traitement de l"athérosclérose.

  化合物I的公式，其中R和Ro中的一个是II，另一个是一级或二级C1-6烷基，C3-6环烷基或苯基-(CH2)m-，其中R4是氢，C1-4烷基，C1-4烷氧基（除t-丁氧基外），三氟甲基，氟，氯，苯氧基或苄氧基，R5是氢，C1-3烷基，C1-3烷氧基，三氟甲基，氟，氯，苯氧基或苄氧基，R5a是氢，C1-2烷基，C1-2烷氧基，氟或氯，m为1、2或3，条件是当R4为氢时，R5和R5a必须都是氢，当R5为氢时，R5a必须是氢，R4和R5中最多只有一个是三氟甲基，最多只有一个是苯氧基，最多只有一个是苄氧基，R2是氢，C1-4烷基，C3-6环烷基，C1-4烷氧基（除t-丁氧基外），三氟甲基，氟，氯，苯氧基或苄氧基，R3是氢，C1-3烷基，C1-3烷氧基，三氟甲基，氟，氯，苯氧基或苄氧基，条件是当R2为氢时，R3必须是氢，R2和R3中最多只有一个是三氟甲基，最多只有一个是苯氧基，最多只有一个是苄氧基，X为-(CH2)n-或-CH=CH-(n=0、1、2或3)，Z为III，其中R6为氢或C1-3烷基，在自由酸形式或生理可水解和可接受的酯或其内酯形式或盐形式中。这些化合物被指示用作药物，特别是用于抑制胆固醇生物合成和治疗动脉粥样硬化。
• Indole analogs of mevalonolactone and derivatives thereof
  申请人：Sandoz Pharm. Corp.

  公开号：US05354772A1

  公开（公告）日：1994-10-11

  Compounds of the formula ##STR1## wherein one of R and R.sub.o is ##STR2## and the other is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom, C.sub.3-6 cycloalkyl or phenyl-(CH.sub.2).sub.m --, wherein R.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R.sub.5 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R.sub.5a is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen, R.sub.5a must be hydrogen when R.sub.5 is hydrogen, not more than one of R.sub.4 and R.sub.5 is trifluoromethyl, not more than one of R.sub.4 and R.sub.5 is phenoxy, and not more than one of R.sub.4 and R.sub.5 is benzyloxy, R.sub.2 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.3-6 cycloalkyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R.sub.3 must be hydrogen when R.sub.2 is hydrogen, not more than one of R.sub.2 and R.sub.3 is trifluoromethyl, not more than one of R.sub.2 and R.sub.3 is phenoxy, and not more than one of R.sub.2 and R.sub.3 is benzyloxy, X is --(CH.sub.2).sub.n -- or --CH.dbd.CH--, wherein n is 0, 1, 2 or 3, and Z is ##STR3## wherein R.sub.6 is hydrogen or C.sub.1-3 alkyl, and R.sub.7 is hydrogen, R.sub.7b or M, wherein R.sub.7b is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level, and therefore, in the treatment of hyperliopoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

  公式为##STR1##的化合物，其中R和R.sub.o中的一个是##STR2##，另一个是不含不对称碳原子的一级或二级C.sub.1-6烷基，C.sub.3-6环烷基或苯基-(CH.sub.2).sub.m --，其中R.sub.4为氢，C.sub.1-3烷基，正丁基，异丁基，叔丁基，C.sub.1-3烷氧基，正丁氧基，异丁氧基，三氟甲基，氟，氯，苯氧基或苄氧基，R.sub.5为氢，C.sub.1-3烷基，C.sub.1-3烷氧基，三氟甲基，氟，氯，苯氧基或苄氧基，R.sub.5a为氢，C.sub.1-2烷基，C.sub.1-2烷氧基，氟或氯，m为1、2或3，条件是当R.sub.4为氢时，R.sub.5和R.sub.5a必须都是氢，当R.sub.5为氢时，R.sub.5a必须是氢，R.sub.4和R.sub.5中不超过一个是三氟甲基，不超过一个是苯氧基，不超过一个是苄氧基，R.sub.2为氢，C.sub.1-3烷基，正丁基，异丁基，叔丁基，C.sub.3-6环烷基，C.sub.1-3烷氧基，正丁氧基，异丁氧基，三氟甲基，氟，氯，苯氧基或苄氧基，R.sub.3为氢，C.sub.1-3烷基，C.sub.1-3烷氧基，三氟甲基，氟，氯，苯氧基或苄氧基，条件是当R.sub.2为氢时，R.sub.3必须是氢，R.sub.2和R.sub.3中不超过一个是三氟甲基，不超过一个是苯氧基，不超过一个是苄氧基，X为--(CH.sub.2).sub.n --或--CH.dbd.CH--，其中n为0、1、2或3，Z为##STR3##其中R.sub.6为氢或C.sub.1-3烷基，R.sub.7为氢，R.sub.7b或M，其中R.sub.7b为生理上可接受且可水解的酯基，M为药学上可接受的阳离子，其用于抑制胆固醇生物合成和降低血液胆固醇水平，因此用于治疗高脂蛋白血症和动脉粥样硬化，包括这种化合物的制药组合物和制备这种化合物的中间体的过程。
• Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
  申请人：SANDOZ AG

  公开号：EP0114027B1

  公开（公告）日：1988-01-07
• US4739073A
  申请人：——

  公开号：US4739073A

  公开（公告）日：1988-04-19